Siebert Matthew J, Makarewich Christopher A
Department of Orthopaedics, University of Utah, 590 Wakara Way, Salt Lake City, UT, 84108, USA.
Primary Children's Hospital, Salt Lake City, UT, USA.
Curr Rev Musculoskelet Med. 2022 Dec;15(6):438-446. doi: 10.1007/s12178-022-09779-y. Epub 2022 Jul 16.
Congenital pseudarthrosis of the tibia (CPT) is a rare condition closely associated with neurofibromatosis type I. Affected children are born with anterolateral bowing of the tibia which progresses to pathologic fracture, pseudarthrosis, and high risk of refracture even after initial union has been attained. There is currently no consensus on the classification of this disease or consensus on its treatment. The purpose of this review is to (1) review the clinical presentation, etiology, epidemiology, classification, and natural history of congenital pseudarthrosis of the tibia and (2) review the existing trends in treatment of congenital pseudarthrosis of the tibia and its associated complications.
Current treatment protocols focus primarily on combining intramedullary fixation with external or internal fixation to achieve union rates between 74 and 100%. Intramedullary devices should be retained as long as possible to prevent refracture. Cross-union techniques, though technically difficult, have a reported union rate of 100% and no refractures at mid- to long-term follow-up. Vascularized fibular grafting and induced membrane technique can be successful, but at the cost of numerous surgical procedures. Growth modulation is a promising new approach to preventing fracture altogether, though further study with larger patient series is necessary. The primary consideration in treatment of CPT is expected union rate and refracture risk. Combined intramedullary and external or internal fixation, especially with cross-union techniques, show most promise. Perhaps most exciting is further research on preventing fracture through guided growth, which may reduce the morbidity of multiple surgical procedures which have been the mainstay of treatment for CPT thus far.
先天性胫骨假关节(CPT)是一种与I型神经纤维瘤病密切相关的罕见病症。患病儿童出生时即有胫骨前外侧弓形弯曲,随后会发展为病理性骨折、假关节,即使在初次愈合后仍有很高的再骨折风险。目前对于该疾病的分类或治疗尚无共识。本综述的目的是:(1)回顾先天性胫骨假关节的临床表现、病因、流行病学、分类及自然病史;(2)回顾先天性胫骨假关节及其相关并发症的现有治疗趋势。
当前的治疗方案主要侧重于将髓内固定与外固定或内固定相结合,以使愈合率达到74%至100%。髓内装置应尽可能长时间保留以防止再骨折。交叉愈合技术虽然技术难度较大,但据报道其愈合率为100%,在中长期随访中无再骨折情况。带血管腓骨移植和诱导膜技术可能成功,但需要进行多次外科手术。生长调节是一种有望完全预防骨折的新方法,不过需要对更多患者系列进行进一步研究。CPT治疗的主要考虑因素是预期愈合率和再骨折风险。髓内固定与外固定或内固定相结合,尤其是交叉愈合技术,显示出最大的前景。也许最令人兴奋的是关于通过引导生长预防骨折的进一步研究,这可能会降低多次外科手术的发病率,而多次外科手术迄今为止一直是CPT治疗的主要手段。